Thomas O’Malley

759 total citations
16 papers, 615 citations indexed

About

Thomas O’Malley is a scholar working on Physiology, Genetics and Epidemiology. According to data from OpenAlex, Thomas O’Malley has authored 16 papers receiving a total of 615 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 8 papers in Genetics and 7 papers in Epidemiology. Recurrent topics in Thomas O’Malley's work include Lysosomal Storage Disorders Research (10 papers), Virus-based gene therapy research (8 papers) and Trypanosoma species research and implications (5 papers). Thomas O’Malley is often cited by papers focused on Lysosomal Storage Disorders Research (10 papers), Virus-based gene therapy research (8 papers) and Trypanosoma species research and implications (5 papers). Thomas O’Malley collaborates with scholars based in United States, Italy and Australia. Thomas O’Malley's co-authors include Mark E. Haskins, Margaret A. Weil, N. Matthew Ellinwood, Katherine P. Ponder, Patricia A. O’Donnell, John R. Melniczek, Lingfei Xu, Meg M. Sleeper, John H. Wolfe and Alberto Auricchio and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Blood.

In The Last Decade

Thomas O’Malley

16 papers receiving 605 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas O’Malley United States	12	373	269	220	190	101	16	615
Margaret A. Weil United States	7	236 0.6×	157 0.6×	134 0.6×	117 0.6×	62 0.6×	7	377
Lingfei Xu United States	12	238 0.6×	466 1.7×	393 1.8×	121 0.6×	81 0.8×	17	764
John R. Melniczek United States	9	155 0.4×	195 0.7×	169 0.8×	69 0.4×	42 0.4×	9	370
Gabriella Cotugno Italy	17	152 0.4×	316 1.2×	383 1.7×	135 0.7×	39 0.4×	37	792
Chantelle McIntyre Australia	14	135 0.4×	197 0.7×	200 0.9×	74 0.4×	40 0.4×	18	411
Bernard Gjata France	15	93 0.2×	330 1.2×	375 1.7×	78 0.4×	82 0.8×	26	694
Carlos A. Saavedra‐Matiz United States	17	146 0.4×	116 0.4×	362 1.6×	133 0.7×	121 1.2×	21	736
Kathleen Meyer United States	11	144 0.4×	219 0.8×	313 1.4×	64 0.3×	29 0.3×	23	469
Stuart Ellison United Kingdom	14	147 0.4×	109 0.4×	250 1.1×	59 0.3×	47 0.5×	27	552
Séverine Charles France	13	85 0.2×	468 1.7×	458 2.1×	113 0.6×	54 0.5×	20	814

Countries citing papers authored by Thomas O’Malley

Since Specialization

Citations

This map shows the geographic impact of Thomas O’Malley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas O’Malley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas O’Malley more than expected).

Fields of papers citing papers by Thomas O’Malley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas O’Malley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas O’Malley. The network helps show where Thomas O’Malley may publish in the future.

Co-authorship network of co-authors of Thomas O’Malley

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas O’Malley. A scholar is included among the top collaborators of Thomas O’Malley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas O’Malley. Thomas O’Malley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Andorko, James I., Ronnie M. Russell, Bruce C. Schnepp, et al.. (2025). Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation. Molecular Therapy. 33(10). 4937–4952. 8 indexed citations

Andorko, James I., Ronnie M. Russell, Bruce C. Schnepp, et al.. (2023). Targeted In Vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform. Blood. 142(Supplement 1). 763–763. 9 indexed citations

Ferla, Rita, Thomas O’Malley, Roberto Calcedo, et al.. (2012). Gene Therapy for Mucopolysaccharidosis Type VI Is Effective in Cats Without Pre-Existing Immunity to AAV8. Human Gene Therapy. 24(2). 163–169. 38 indexed citations

Ponder, Katherine P., Thomas O’Malley, Ping Wang, et al.. (2012). Neonatal Gene Therapy With a Gamma Retroviral Vector in Mucopolysaccharidosis VI Cats. Molecular Therapy. 20(5). 898–907. 20 indexed citations

Kennedy, Jeffrey S., William Vernau, Peter F. Moore, et al.. (2011). Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma. Veterinary Immunology and Immunopathology. 142(1-2). 36–48. 5 indexed citations

Cotugno, Gabriella, Patrizia Annunziata, Alessandra Tessitore, et al.. (2010). Long-term Amelioration of Feline Mucopolysaccharidosis VI After AAV-mediated Liver Gene Transfer. Molecular Therapy. 19(3). 461–469. 60 indexed citations

Suter, Steven E., Thomas O’Malley, Peter A. McSweeney, et al.. (2007). Marking of peripheral T-lymphocytes by retroviral transduction and transplantation of CD34+ cells in a canine X-linked severe combined immunodeficiency model. Veterinary Immunology and Immunopathology. 117(3-4). 183–196. 5 indexed citations

Ellinwood, N. Matthew, Marie‐Anne Colle, Margaret A. Weil, et al.. (2007). Bone marrow transplantation for feline mucopolysaccharidosis I. Molecular Genetics and Metabolism. 91(3). 239–250. 21 indexed citations

Tessitore, Alessandra, Armida Faella, Thomas O’Malley, et al.. (2007). Biochemical, Pathological, and Skeletal Improvement of Mucopolysaccharidosis VI After Gene Transfer to Liver but Not to Muscle. Molecular Therapy. 16(1). 30–37. 64 indexed citations

10.

Wang, Bin, Thomas O’Malley, Lingfei Xu, et al.. (2005). Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Molecular Genetics and Metabolism. 87(1). 8–21. 33 indexed citations

11.

Carmichael, K. Paige, et al.. (2004). Mucopolysaccharidosis type VII in a German Shepherd Dog. Journal of the American Veterinary Medical Association. 224(4). 553–557. 23 indexed citations

12.

Sleeper, Meg M., Benedetta Elena Fornasari, N. Matthew Ellinwood, et al.. (2004). Gene Therapy Ameliorates Cardiovascular Disease in Dogs With Mucopolysaccharidosis VII. Circulation. 110(7). 815–820. 39 indexed citations

13.

Xu, Lingfei, Mark E. Haskins, John R. Melniczek, et al.. (2002). Transduction of Hepatocytes after Neonatal Delivery of a Moloney Murine Leukemia Virus Based Retroviral Vector Results in Long-Term Expression of β-Glucuronidase in Mucopolysaccharidosis VII Dogs. Molecular Therapy. 5(2). 141–153. 57 indexed citations

14.

Ponder, Katherine P., John R. Melniczek, Lingfei Xu, et al.. (2002). Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proceedings of the National Academy of Sciences. 99(20). 13102–13107. 132 indexed citations

15.

Kakkis, Emil, Edward H. Schuchman, Xingxuan He, et al.. (2001). Enzyme Replacement Therapy in Feline Mucopolysaccharidosis I. Molecular Genetics and Metabolism. 72(3). 199–208. 74 indexed citations

16.

Sammarco, Carl D., Margaret A. Weil, Thomas O’Malley, et al.. (2000). Effects of bone marrow transplantation on the cardiovascular abnormalities in canine mucopolysaccharidosis VII. Bone Marrow Transplantation. 25(12). 1289–1297. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact